

JosÃ© Alexandre de Souza Crippa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2165013/publications.pdf>

Version: 2024-02-01

154
papers

8,074
citations

61984

43
h-index

56724

83
g-index

161
all docs

161
docs citations

161
times ranked

7695
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 15-20.	1.7	7
2	Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 658-669.	2.9	22
3	Harmine impairs memory performance of treated rats and nontreated cagemates.. <i>Experimental and Clinical Psychopharmacology</i> , 2022, 30, 751-759.	1.8	2
4	Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. <i>Psychopharmacology</i> , 2022, 239, 1499-1507.	3.1	15
5	Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer's Disease Rat Model: A Proof-of-Concept Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1076.	4.1	12
6	Circulating Endocannabinoids in Huntington's Disease: An Exploratory Cross-Sectional Study. <i>Journal of Huntington's Disease</i> , 2022, , 1-5.	1.9	0
7	The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 298-307.	1.7	11
8	Monitoring the Mental Health and Professional Overload of Health Workers in Brazil: A Longitudinal Study Considering the First Wave of the COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2022, 13, 852157.	2.6	7
9	Is it the Ideal Time to Start Prescribing Cannabis Derivatives to Treat Endometriosis-associated Pain?. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 449-451.	0.8	0
10	Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action. <i>Metabolic Brain Disease</i> , 2021, 36, 639-652.	2.9	27
11	Memory Bias and Personality Characteristics in College Students with Social Anxiety Disorder. <i>Trends in Psychiatry and Psychotherapy</i> , 2021, , .	0.8	1
12	A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 37-40.	2.2	3
13	Cannabidiol as a Treatment for Mental Health Outcomes Among Health Care Workers During the Coronavirus Disease Pandemic. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 327-329.	1.4	12
14	Risk and Protective Factors for the Mental Health of Brazilian Healthcare Workers in the Frontline of COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2021, 12, 662742.	2.6	23
15	Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2120603.	5.9	47
16	Cannabidiol reverses memory impairments and activates components of the Akt/GSK3 β pathway in an experimental model of estrogen depletion. <i>Behavioural Brain Research</i> , 2021, 417, 113555.	2.2	3
17	Cortical surface abnormalities are different depending on the stage of schizophrenia: A cross-sectional vertexwise mega-analysis of thickness, area and gyrification. <i>Schizophrenia Research</i> , 2021, 236, 104-114.	2.0	9
18	Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1264, 29-45.	1.6	47

#	ARTICLE	IF	CITATIONS
19	Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Revista Brasileira De Psiquiatria, 2021, 43, 467-476.	1.7	26
20	The first department of medical psychology in the world and its impact on medical education. Revista Brasileira De Psiquiatria, 2021, , .	1.7	0
21	Increased body sway in phobic patients exposed to images of spiders. Revista Brasileira De Psiquiatria, 2021, 43, 477-483.	1.7	0
22	Oral Cannabidiol Does Not Convert to Î” ⁸ -THC or Î” ⁹ -THC in Humans: A Pharmacokinetic Study in Healthy Subjects. Cannabis and Cannabinoid Research, 2020, 5, 89-98.	2.9	30
23	Biological bases for a possible effect of cannabidiol in Parkinson’s disease. Revista Brasileira De Psiquiatria, 2020, 42, 218-224.	1.7	18
24	In-tube solid-phase microextraction with a dummy molecularly imprinted monolithic capillary coupled to ultra-performance liquid chromatography-tandem mass spectrometry to determine cannabinoids in plasma samples. Analytica Chimica Acta, 2020, 1099, 145-154.	5.4	34
25	Cannabidiol-induced panicolytic-like effects and fear-induced antinociception impairment: the role of the CB1 receptor in the ventromedial hypothalamus. Psychopharmacology, 2020, 237, 1063-1079.	3.1	8
26	Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal of Psychopharmacology, 2020, 34, 189-196.	4.0	69
27	The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: A systematic review of randomized controlled trials. Neuroscience and Biobehavioral Reviews, 2020, 118, 236-246.	6.1	9
28	Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias. Journal of Neural Transmission, 2020, 127, 1359-1367.	2.8	13
29	Prof. Elisaldo Araújo Carlini, Cannabis and Cannabinoids Research Pioneer (June 9, 1930–September 16,) Tj ETQq1.1 0.784314 rgB	2.9	0
30	Proneness, urbanicity, trauma, and cannabis triggering psychotic states in large urban centers. Current Opinion in Psychiatry, 2020, 33, 250-254.	6.3	1
31	Ensuring access to safe, effective, and affordable cannabis-based medicines. British Journal of Clinical Pharmacology, 2020, 86, 630-634.	2.4	14
32	Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 517-526.	3.3	46
33	Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes. Neuroscience Letters, 2020, 729, 135020.	2.1	16
34	Intraperitoneal cannabidiol attenuates neonatal germinal matrix hemorrhage-induced neuroinflammation and perilesional apoptosis. Neurological Research, 2019, 41, 980-990.	1.3	9
35	Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder. CNS Drugs, 2019, 33, 1031-1038.	5.9	14
36	Clinical validity and intrarater and test-retest reliability of the Structured Clinical Interview for DSM-5 – Clinician Version (SCID-5/CV). Psychiatry and Clinical Neurosciences, 2019, 73, 754-760.	1.8	145

#	ARTICLE	IF	CITATIONS
37	Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 121-133.	3.2	41
38	Personality Inventory for DSM-5 (PID-5): cross-cultural adaptation and content validity in the Brazilian context. Trends in Psychiatry and Psychotherapy, 2019, 41, 297-300.	0.8	11
39	Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit. Neuropharmacology, 2019, 155, 44-53.	4.1	15
40	Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531984577.	2.7	25
41	O uso do canabidiol (CBD) no tratamento da doena de Parkinson e suas comorbidades. , 2019, 98, 46-51.	0.1	3
42	Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. Brain Research, 2019, 1715, 156-164.	2.2	67
43	The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression. Neuroscience and Biobehavioral Reviews, 2019, 101, 78-84.	6.1	51
44	DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-B activity dependent on A2A receptor. Toxicology and Applied Pharmacology, 2019, 368, 63-71.	2.8	33
45	Association Between Physician Depressive Symptoms and Medical Errors. JAMA Network Open, 2019, 2, e1916097.	5.9	88
46	Epigenetic variation at the SLC6A4 gene promoter in mother-child pairs with major depressive disorder. Journal of Affective Disorders, 2019, 245, 716-723.	4.1	17
47	Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol. Brain Research Bulletin, 2018, 139, 1-8.	3.0	38
48	The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users. Cannabis and Cannabinoid Research, 2018, 3, 1-10.	2.9	17
49	Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans. Journal of Clinical Psychopharmacology, 2018, 38, 644-646.	1.4	8
50	Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload. Translational Psychiatry, 2018, 8, 176.	4.8	50
51	Cross-cultural adaptation and psychometric assessment of a Brazilian-Portuguese version of the Resident Questionnaire. PLoS ONE, 2018, 13, e0203531.	2.5	3
52	Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Frontiers in Immunology, 2018, 9, 2009.	4.8	187
53	17.4 POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD). Schizophrenia Bulletin, 2018, 44, S28-S28.	4.3	1
54	Clinical issues in cannabis use. British Journal of Clinical Pharmacology, 2018, 84, 2495-2498.	2.4	20

#	ARTICLE	IF	CITATIONS
55	No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. <i>Frontiers in Pharmacology</i> , 2018, 9, 315.	3.5	70
56	Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?. <i>Frontiers in Pharmacology</i> , 2018, 9, 482.	3.5	110
57	Borderline personality disorder and bias in the recognition of facial expressions of emotion: a pathway to understand the psychopathology. <i>Revista De Psiquiatria Clinica</i> , 2018, 45, 7-11.	0.6	5
58	Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System. <i>CNS Drugs</i> , 2018, 32, 697-712.	5.9	37
59	Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia. <i>Frontiers in Pharmacology</i> , 2018, 9, 901.	3.5	36
60	Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases. <i>Analytica Chimica Acta</i> , 2018, 1044, 12-28.	5.4	43
61	Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. <i>Chemico-Biological Interactions</i> , 2018, 291, 81-86.	4.0	29
62	Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats. <i>Neuroscience Letters</i> , 2018, 682, 62-68.	2.1	23
63	Neuroimaging of major depression in Parkinson's disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings. <i>Journal of Psychiatric Research</i> , 2017, 90, 40-45.	3.1	27
64	Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report. <i>Journal of Psychedelic Studies</i> , 2017, 1, 35-39.	1.2	5
65	Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 698-711.	2.1	111
66	A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3587-3596.	3.7	33
67	Selective post-training time window for memory consolidation interference of cannabidiol into the prefrontal cortex: Reduced dopaminergic modulation and immediate gene expression in limbic circuits. <i>Neuroscience</i> , 2017, 350, 85-93.	2.3	32
68	A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 81-86.	2.9	47
69	Psychometric properties of the dimensional anxiety scales for DSM-5 in a Brazilian community sample. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, .	2.1	10
70	Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy. <i>Frontiers in Pharmacology</i> , 2017, 8, 131.	3.5	56
71	Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats. <i>Frontiers in Pharmacology</i> , 2017, 8, 391.	3.5	36
72	Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): transcultural adaptation of the Brazilian version. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 10-19.	0.6	28

#	ARTICLE	IF	CITATIONS
73	Early interventions for the prevention of PTSD in adults: a systematic literature review. Revista De Psiquiatria Clinica, 2017, 44, 23-29.	0.6	10
74	Can anxiety increase tremors in patients with Parkinson's disease? An experimental model. Revista De Psiquiatria Clinica, 2017, 44, 85-88.	0.6	5
75	False memories in social anxiety disorder. Revista De Psiquiatria Clinica, 2017, 44, 113-116.	0.6	0
76	Determination of Drugs in Plasma Samples by High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Schizophrenic Patients. Journal of Analytical Toxicology, 2016, 40, bkv107.	2.8	34
77	Mental health in medical residents: relationship with personal, work-related, and sociodemographic variables. Revista Brasileira De Psiquiatria, 2016, 38, 318-324.	1.7	13
78	Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. PLoS ONE, 2016, 11, e0158779.	2.5	35
79	Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Revista Brasileira De Psiquiatria, 2016, 38, 65-72.	1.7	98
80	Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Frontiers in Pharmacology, 2016, 7, 303.	3.5	24
81	Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats. Frontiers in Pharmacology, 2016, 7, 343.	3.5	46
82	Î9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol. Frontiers in Pharmacology, 2016, 7, 359.	3.5	60
83	Heritability of social anxiety disorder: a systematic review of methodological designs. Revista De Psiquiatria Clinica, 2016, 43, 83-92.	0.6	10
84	Factor Structure, Reliability, and Item Parameters of the Brazilian-Portuguese Version of the GAD-7 Questionnaire. Temas Em Psicologia, 2016, 24, 367-376.	0.3	101
85	Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. Journal of Psychoactive Drugs, 2016, 48, 195-205.	1.7	65
86	Facial emotion recognition in social anxiety: The influence of dynamic information.. Psychology and Neuroscience, 2016, 9, 1-11.	0.8	24
87	Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. NeuroImage: Clinical, 2016, 12, 1-15.	2.7	107
88	Classical hallucinogens and neuroimaging: A systematic review of human studies. Neuroscience and Biobehavioral Reviews, 2016, 71, 715-728.	6.1	79
89	Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. Journal of Clinical Psychopharmacology, 2016, 36, 77-81.	1.4	364
90	Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology, 2016, 6, 193-213.	2.7	204

#	ARTICLE	IF	CITATIONS
91	Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia. <i>Schizophrenia Research</i> , 2016, 172, 220-221.	2.0	22
92	Letter to the Editor. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2016, 38, 116-117.	1.0	1
93	Facial emotion processing in patients with social anxiety disorder and Williams's Beuren syndrome: an fMRI study. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 182-191.	2.4	20
94	The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network. <i>PLoS ONE</i> , 2015, 10, e0118143.	2.5	308
95	Editorial (Thematic Issue: Translational Neuroscience: Narrowing Distances for Future Discoveries). <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 962-962.	1.4	1
96	Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. <i>European Neuropsychopharmacology</i> , 2015, 25, 483-492.	0.7	145
97	Dissociation between the panicolytic effect of cannabidiol microinjected into the substantia nigra, pars reticulata, and fear-induced antinociception elicited by bicuculline administration in deep layers of the superior colliculus: The role of CB1-cannabinoid receptor in the ventral mesencephalon. <i>European Journal of Pharmacology</i> , 2015, 758, 153-163.	3.5	24
98	Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (<i>Danio rerio</i>). <i>Pharmacology Biochemistry and Behavior</i> , 2015, 135, 210-216.	2.9	32
99	Phytocannabinoids and epilepsy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 135-143.	1.5	60
100	Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins. <i>Molecular Neurobiology</i> , 2015, 52, 26-37.	4.0	30
101	Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 970-978.	1.4	10
102	Evaluation of the Psychometric Properties of the Cognitive Distortions Questionnaire (CD-Quest) in a Sample of Undergraduate Students. <i>Innovations in Clinical Neuroscience</i> , 2015, 12, 20-7.	0.1	27
103	Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. <i>Frontiers in Pharmacology</i> , 2014, 5, 10.	3.5	59
104	Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 30-36.	2.7	21
105	Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial. <i>Journal of Psychopharmacology</i> , 2014, 28, 1088-1098.	4.0	244
106	Cannabidiol and endogenous opioid peptide-mediated mechanisms modulate antinociception induced by transcutaneous electrostimulation of the peripheral nervous system. <i>Journal of the Neurological Sciences</i> , 2014, 347, 82-89.	0.6	13
107	Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection. <i>Molecular Neurobiology</i> , 2014, 49, 222-233.	4.0	69
108	Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 953-960.	1.4	116

#	ARTICLE	IF	CITATIONS
109	Neuroimaging of depression in Parkinson's disease: a review. <i>International Psychogeriatrics</i> , 2013, 25, 1953-1961.	1.0	26
110	Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. <i>Journal of Psychopharmacology</i> , 2013, 27, 312-316.	4.0	64
111	Disability Profile/Clinician-Rated: Validity for Brazilian University Students with Social Anxiety Disorder. <i>Spanish Journal of Psychology</i> , 2013, 16, E48.	2.1	1
112	Cannabidiol for the treatment of <i>cannabis</i> withdrawal syndrome: a case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 162-164.	1.5	82
113	Assessment of referrals to an OT consultation-liaison service: a retrospective and comparative study. <i>Scandinavian Journal of Occupational Therapy</i> , 2012, 19, 84-91.	1.7	1
114	A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation. <i>Current Pharmaceutical Design</i> , 2012, 18, 5131-5140.	1.9	174
115	Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, S104-S117.	1.7	64
116	Utiliza��o do Invent��rio de Habilidades sociais no diagn��stico do Transtorno de Ansiedade Social. <i>Psicologia: Reflexao E Critica</i> , 2012, 25, 467-476.	0.9	10
117	Transtorno de ansiedade social e habilidades sociais de falar em p��blico: estudo experimental. <i>Estudos E Pesquisas Em Psicologia</i> , 2012, 12, .	0.1	2
118	Aspectos cognitivos do falar em p��blico: valida��o de uma escala de autoavalia��o para universit��rios brasileiros. <i>Revista De Psiquiatria Clinica</i> , 2012, 39, 48-53.	0.6	13
119	Social phobia in Brazilian university students: Prevalence, under-recognition and academic impairment in women. <i>Journal of Affective Disorders</i> , 2012, 136, 857-861.	4.1	57
120	Interaction between cannabidiol (CBD) and ��9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. <i>Psychopharmacology</i> , 2012, 219, 247-249.	3.1	78
121	Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, S104-S117.	1.7	47
122	Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Na��ve Social Phobia Patients. <i>Neuropsychopharmacology</i> , 2011, 36, 1219-1226.	5.4	585
123	Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. <i>Journal of Psychopharmacology</i> , 2011, 25, 121-130.	4.0	406
124	Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2011, 125, 1-12.	2.0	69
125	Further psychometric study of the Beck Anxiety Inventory including factorial analysis and social anxiety disorder screening. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 255-262.	2.4	35
126	Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 877-886.	4.8	40

#	ARTICLE	IF	CITATIONS
127	Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent. Current Drug Safety, 2011, 6, 237-249.	0.6	422
128	Altered gray matter morphometry and resting-state functional and structural connectivity in social anxiety disorder. Brain Research, 2011, 1388, 167-177.	2.2	142
129	Social anxiety disorder women easily recognize fearfull, sad and happy faces: The influence of gender. Journal of Psychiatric Research, 2010, 44, 535-540.	3.1	62
130	Further Study of the Psychometric Qualities of a Brief Screening Tool for Social Phobia (MINI-SPIN) Applied to Clinical and Nonclinical Samples. Perspectives in Psychiatric Care, 2010, 46, 266-278.	1.9	19
131	Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Revista Brasileira De Psiquiatria, 2010, 32, 56-61.	1.7	121
132	The Fast Alcohol Screening Test (FAST) is as Good as the AUDIT to Screen Alcohol Use Disorders. Substance Use and Misuse, 2010, 45, 1542-1557.	1.4	21
133	Evaluation of the psychometric properties of the Social Phobia Inventory in university students. Comprehensive Psychiatry, 2010, 51, 630-640.	3.1	32
134	Neuroimaging in social anxiety disorder: A systematic review of the literature. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 565-580.	4.8	242
135	Agomelatine in the treatment of social anxiety disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1357-1358.	4.8	14
136	Instituto Nacional de Ciãncia e Tecnologia em Medicina Translacional (INCT-TM): abordagens metodolãgicas. Revista Brasileira De Psiquiatria, 2010, 32, 83-90.	1.7	13
137	Cannabis sativa: a planta que pode produzir efeitos indesejãveis e tambã©m tratã-los. Revista Brasileira De Psiquiatria, 2010, 32, 51-52.	1.7	15
138	Cross- cultural validation of the Brazilian Portuguese version of the Social Phobia Inventory (SPIN): study of the items and internal consistency. Revista Brasileira De Psiquiatria, 2009, 31, 25-29.	1.7	39
139	Arthur Bispo do Rosãrio (1909?-1989): Insanity and Art. American Journal of Psychiatry, 2009, 166, 1117-1117.	7.2	0
140	Does social phobia remain the 'Ugly Duckling' of anxiety disorders?. Revista Brasileira De Psiquiatria, 2009, 31, 297-299.	1.7	13
141	Magnetic resonance spectroscopy in anxiety disorders. Acta Neuropsychiatrica, 2008, 20, 56-71.	2.1	20
142	Comparability Between Telephone and Face-to-Face Structured Clinical Interview for<i>DSM-IV</i> in Assessing Social Anxiety Disorder. Perspectives in Psychiatric Care, 2008, 44, 241-247.	1.9	96
143	Structural magnetic ressonance imaging in anxiety disorders: an update of research findings. Revista Brasileira De Psiquiatria, 2008, 30, 251-264.	1.7	63
144	Escala para auto-avaliaã©o ao falar em pãblico (SSPS): adaptaã©o transcultural e consistãncia interna da versã©o brasileira. Revista De Psiquiatria Clinica, 2008, 35, 207-211.	0.6	23

#	ARTICLE	IF	CITATIONS
145	Are there differences between early- and late-onset social anxiety disorder?. Revista Brasileira De Psiquiatria, 2007, 29, 195-196.	1.7	15
146	Cavum septum pellucidum and adhesio interthalamica in schizophrenia: an MRI study. European Psychiatry, 2006, 21, 291-299.	0.2	47
147	Cross-cultural validation of the Brief Social Phobia Scale for use in Portuguese and the development of a structured interview guide. Revista Brasileira De Psiquiatria, 2006, 28, 212-217.	1.7	11
148	Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow. Neuropsychopharmacology, 2004, 29, 417-426.	5.4	239
149	Electrodermically Nonresponsive Schizophrenia Patients Make More Errors in the Stroop Color Word Test, Indicating Selective Attention Deficit. Schizophrenia Bulletin, 2002, 28, 459-466.	4.3	11
150	Lipoma adhered to the corpus callosum in a schizophrenic patient with severe positive symptoms that responded to clozapine. Acta Neuropsychiatrica, 2002, 14, 36-38.	2.1	5
151	Structural imaging of other anxiety disorders. , 0, , 274-287.		0
152	Social Anxiety Disorder, Fear of Public Speaking, and the use of Assessment Instruments. , 0, , .		2
153	Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations. Frontiers in Pharmacology, 0, 13, .	3.5	8
154	The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A <i>Post Hoc</i> Exploratory Analysis of Phase 2/3 Clinical Trial. Cannabis and Cannabinoid Research, 0, , .	2.9	4